{"id":"dcv-3daa","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This triple direct-acting antiviral (3DAA) regimen targets multiple steps of the hepatitis C virus lifecycle simultaneously. By combining protease, polymerase, and NS5A inhibitors, the combination achieves high barrier to resistance and broad genotype coverage, enabling high cure rates across diverse patient populations with chronic hepatitis C.","oneSentence":"DCV 3DAA is a fixed-dose combination of three direct-acting antivirals that inhibit hepatitis C virus NS3/4A protease, NS5B polymerase, and NS5A protein to block viral replication.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:48.136Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection (genotype 1-6)"}]},"trialDetails":[{"nctId":"NCT01979939","phase":"PHASE3","title":"UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-12","conditions":"Hepatitis C","enrollment":416},{"nctId":"NCT01973049","phase":"PHASE3","title":"UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-12","conditions":"Hepatitis C","enrollment":202},{"nctId":"NCT02123654","phase":"PHASE3","title":"UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis C","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-04","conditions":"Hepatitis C Virus Infection","enrollment":297},{"nctId":"NCT02175602","phase":"PHASE1","title":"Study of Drug Combination on Pharmacokinetics in Healthy Volunteers","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-06","conditions":"Hepatitis C Infection","enrollment":41},{"nctId":"NCT02095860","phase":"PHASE1","title":"Food Effect of a Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-04","conditions":"Hepatitis C","enrollment":24},{"nctId":"NCT02103569","phase":"PHASE1","title":"Drug Interaction Study of an OCP (Norethindrone (ND) Acetate and Ethinyl Estradiol (EE))With a Combination of Daclatasvir (DCV) Asunaprevir (ASV) and BMS-791325","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-04","conditions":"Hepatitis C","enrollment":20},{"nctId":"NCT02108639","phase":"PHASE1","title":"To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-04","conditions":"Hepatitis C","enrollment":41},{"nctId":"NCT02045966","phase":"PHASE1","title":"Study to Determine the Potential DDIs When the Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-02","conditions":"Hepatitis C","enrollment":16},{"nctId":"NCT02045693","phase":"PHASE1","title":"Drug Interaction & Methadone & Buprenorphine","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-02","conditions":"Hepatitis C","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Daclatasvir 30 mg /Asunaprevir 200 mg /BMS-791325 75 mg fixed dose combination"],"phase":"phase_3","status":"active","brandName":"DCV 3DAA","genericName":"DCV 3DAA","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DCV 3DAA is a fixed-dose combination of three direct-acting antivirals that inhibit hepatitis C virus NS3/4A protease, NS5B polymerase, and NS5A protein to block viral replication. Used for Chronic hepatitis C virus infection (genotype 1-6).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}